MX2025007584A - Sales y formas solidas del intermedio sonrotoclax - Google Patents

Sales y formas solidas del intermedio sonrotoclax

Info

Publication number
MX2025007584A
MX2025007584A MX2025007584A MX2025007584A MX2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A MX 2025007584 A MX2025007584 A MX 2025007584A
Authority
MX
Mexico
Prior art keywords
sonrotoclax
salts
solid forms
processes
preparation
Prior art date
Application number
MX2025007584A
Other languages
English (en)
Inventor
Liwen Xu
Kai Peng
Quanyou Yao
Juntao Liu
Qun Jiang
Original Assignee
Beone Medicines I Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beone Medicines I Gmbh filed Critical Beone Medicines I Gmbh
Publication of MX2025007584A publication Critical patent/MX2025007584A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En este documento se describen sales y formas sólidas del intermedio sonrotoclax y procesos para su preparación.
MX2025007584A 2022-12-27 2025-06-26 Sales y formas solidas del intermedio sonrotoclax MX2025007584A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2022142316 2022-12-27
PCT/CN2023/141989 WO2024140692A1 (en) 2022-12-27 2023-12-26 Salts and solid forms of sonrotoclax intermediate

Publications (1)

Publication Number Publication Date
MX2025007584A true MX2025007584A (es) 2025-09-02

Family

ID=91716479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025007584A MX2025007584A (es) 2022-12-27 2025-06-26 Sales y formas solidas del intermedio sonrotoclax

Country Status (10)

Country Link
US (1) US20250320209A1 (es)
EP (1) EP4642776A1 (es)
JP (1) JP2026503230A (es)
KR (1) KR20250127312A (es)
CN (1) CN119301117A (es)
AU (1) AU2023416871A1 (es)
IL (1) IL321700A (es)
MX (1) MX2025007584A (es)
TW (1) TW202434586A (es)
WO (1) WO2024140692A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112437772B (zh) * 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
WO2021083135A1 (en) * 2019-10-28 2021-05-06 Beigene, Ltd. Bcl-2 INHIBITORS
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor
MX2023014275A (es) * 2021-06-02 2024-03-06 Beigene Switzerland Gmbh Métodos de tratamiento de la malignidad de células b utilizando un inhibidor de bcl-2.
TW202400163A (zh) * 2022-05-12 2024-01-01 英屬開曼群島商百濟神州有限公司 使用bcl-2抑制劑治療髓性惡性腫瘤之方法

Also Published As

Publication number Publication date
IL321700A (en) 2025-08-01
TW202434586A (zh) 2024-09-01
KR20250127312A (ko) 2025-08-26
WO2024140692A1 (en) 2024-07-04
CN119301117A (zh) 2025-01-10
US20250320209A1 (en) 2025-10-16
JP2026503230A (ja) 2026-01-28
AU2023416871A1 (en) 2025-08-14
EP4642776A1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
MY209340A (en) Egfr inhibitor for the treatment of cancer
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2022015597A (es) Formas en estado solido de ciantraniliprol.
WO2022192414A3 (en) Synthesis of omecamtiv mecarbil
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
MX2025003937A (es) Formas cristalinas de un agente anti-sars cov-2
MX2025012200A (es) Sintesis de inhibidores de ras
MX2023006512A (es) Método para preparar pralsetinib.
PH12022550491A1 (en) Perk inhibiting pyrrolopyrimidine compounds
PH12021550403A1 (en) Process of making calcium alpha-ketoglutarate
ZA202103228B (en) Crystal forms of an alk2 inhibitor
EP4480538A3 (en) Solid state forms of mavacamten and process for preparation thereof
PH12022550497A1 (en) Perk inhibiting compounds
MX2025007384A (es) Inhibidores de malt1
WO2020018751A9 (en) Methods and kits of using an implant for tissue repair
MX2025008454A (es) Inhibidores de mptp
MX2025013242A (es) Quinoxalinas sustituidas
MX2024014450A (es) Composiciones de genoterapia y metodos de uso de las mismas
MX2025007548A (es) Pirroloquinazolinonas espirociclicas sustituidas y piperidinoquinazolinonas espirociclicas sustituidas
IL279168B (en) A process for the preparation of eribulin
WO2021118924A3 (en) Compositions and methods for the prevention and treatment of hearing loss
EP4353230A3 (en) Solid state forms of asciminib and process for preparation thereof
MX2022013961A (es) Sintesis de productos intermedios de sulfonamida.
JOP20230034A1 (ar) مثبطات إفراز البروتين